Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Drug/Device Combination Product Receives FDA Approval For COPD

By Pari Pharma GmbH | December 7, 2017

Pari Pharma’s nebulizer Magnair together with Sunovion’s Lonhala (glycopyrrolate) inhalation system. (Credit: Pari Pharma GmbH and Sunovion)

Magnair, an eFlow closed system nebulizer, together with Sunovion’s Lonhala is the first eFlow technology-based product to receive FDA approval to treat chronic obstructive pulmonary disease (COPD).

Pari Pharma GmbH, a company focused on the development and commercialization of advanced aerosol delivery systems based on eFlow technology, announced approval of its first eFlow closed system nebulizer Magnair together with Sunovion Pharmaceutical Inc.‘s Lonhala (glycopyrrolate) inhalation system.

The Lonhala Magnair drug/device combination product received FDA approval on December 5th, 2017 under a New Drug Application (NDA).

Magnair, designed, optimized, and developed by Pari Pharma, is intended only for use with the Lonhala (glycopyrrolate) inhalation vials in patients with COPD. Magnair is the first product to be commercialized using Pari’s eFlow closed system nebulizer technology, which does not have a traditional open medication reservoir in which patients manually transfer the liquid drug product from a vial.

Magnair has a proprietary blow-fill-seal ampule that is inserted into the cap of Magnair and pierced open once the cap of the Magnair handset is closed, without the need for a manual filling step. This feature is designed to reduce risk of spilling of the medication when the vial is emptied.

As with all eFlow technology nebulizers, Magnair allows the patient to breathe naturally without any special breathing technique. The patient inhales and exhales as they normally do at rest. 

“So far, eFlow Technology nebulizers like Altera, Zirela, Tolero, or eRapid/eFlowRapid are available to patients suffering from the orphan indication of cystic fibrosis,” Dr. Martin Knoch, president of Pari Pharma, said. “With the approval of Lonhala Magnair for COPD, we are bringing a new advancement in nebulizers that are designed to be efficient, silent, and fast to people with COPD.”

Pari Pharma develops aerosol delivery devices optimized with drug products for nebulized treatments using proprietary technologies.  The company is located near Munich, Germany with a significant presence in the United States.

(Sources: Pari Pharma GmbH and Sunovion Pharmaceuticals Inc.)

Related Articles Read More >

This is a Hemco marketing image of its MicroFlow self-contained workstation.
Hemco highlights its self-contained workstations
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Moving toward the autonomous lab and what’s possible today
Female worker at pharmaceutical factory operating control panel of the pharmaceutical machine.
How real-time sensors and data-savvy can cut energy waste in pharma
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE